US2020085825A1PendingUtilityA1

Novel pharmaceutical formulations and their use in the treatment of periodontal disease

56
Assignee: PERIOC LTDPriority: Dec 13, 2012Filed: Oct 2, 2019Published: Mar 19, 2020
Est. expiryDec 13, 2032(~6.4 yrs left)· nominal 20-yr term from priority
Inventors:Thomas KisselChing-Pong Mak
A61K 31/155A61K 47/10A61K 47/34A61K 47/50A61K 31/5025A61K 38/13A61K 38/03A61K 9/0063A61K 9/145A61K 38/15A61K 9/10A61K 47/22C07K 7/645A61K 31/355A61P 1/02
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds.

Claims

exact text as granted — not AI-modified
1 . A method of treating periodontal disease in a subject, comprising administering an effective amount of a pharmaceutical formulation comprising micro or nanoparticles of cyclosporin A to the subject wherein the formulation contains TPGS (Tocopheryl Polyethylene Glycol Succinate). 
     
     
         2 . The method according to  claim 1  wherein the formulation is applied into the gingival pocket. 
     
     
         3 . The method according to  claim 1  wherein the formulation further comprises a poloxamer. 
     
     
         4 . The method according to  claim 1  wherein the formulation comprises 1% TPGS and 1% Poloxamer 407. 
     
     
         5 . The method according to  claim 1  wherein the formulation is liquid upon application, but forms a gel in-situ. 
     
     
         6 . The method according to  claim 1  wherein the cyclosporin A is crystalline. 
     
     
         7 . The method according to  claim 1  wherein the cyclosporin A is micronized before formulation. 
     
     
         8 . The method according to  claim 1  wherein the formulation consists of particles where greater than 50% of the particles are less than 1 micrometer in diameter. 
     
     
         9 . The method according to  claim 1  wherein the formulation further comprises a mucoadhesive. 
     
     
         10 . The method according to  claim 9  wherein the mucoadhesive is selected from lectins, carbopol (polyacrylic acid), chitosan, hydroxyethyl cellulose, hydroxypropyl cellulose, or sodium carboxymethyl cellulose. 
     
     
         11 . The method according to  claim 1  wherein the formulation further comprises an antimicrobial preservative. 
     
     
         12 . The method according to  claim 1  wherein the formulation is formulated with 15-20% poloxamer 407. 
     
     
         13 . The method according to  claim 1  wherein the formulation is formulated with hydroxypropyl methylcellulose HPMC. 
     
     
         14 . The method according to  claim 1  wherein the periodontal disease affects humans or canines. 
     
     
         15 . The method according to  claim 1  wherein the formulation is administered topically. 
     
     
         16 . The method according to  claim 2  wherein the formulation is administered by injection into the gum.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.